...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...treatment of metastatic pancreatic cancer and a Phase II trial to treat platinum-resistant ovarian cancer. Morvus Technology Ltd....
...U.K. Product: Acelarin (NUC-1031) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus'...

...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...and a Phase II trial to treat platinum-resistant ovarian cancer. Elizabeth S. Eaton Acelarin cisplatin gemcitabine NUC-1031 American Society of Clinical Oncology Morvus Technology Ltd. NuCana...

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
...NUC-1031 , MTL-007 ) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus’...

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....

...of therapy is very impressive," Healy said. NuCana has rights to the ProTide technology from Morvus Technology Ltd. ...

...cell lung cancer (NSCLC). Acelarin is a modified version of gemcitabine using ProTide technology from Morvus Technology Ltd....

...Morvus' ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....

...and Alida Capital International also participated. NuCana has exclusive, worldwide rights to ProTide technology from Morvus Technology Ltd....

...compound optimization. Bayer AG markets Lampit nifurtimox, an antiprotozoal nitrofuran derivative, to treat trypanosome infection. Morvus Technology Ltd.'s...

...malaria. Pfizer's macrolide antibiotic Zithromax azithromycin is in Phase III testing to treat pediatric malaria. Morvus Technology Ltd.'s...